Adverse clinical outcomes in patients undergoing both PCI and TAVR: Analysis from a pooled multi-center registry.
Arnav KumarYasser SammourShawn ReginauldKimi SatoNikhil AgrawalJoo-Myung LeeChandramohan MeenakshisundaramThammi RamananNorihiko KamiokaAbhishek C SawantDivyanshu MohananeyPatrick T GleasonChandan DevireddyAmar KrishnaswamyKreton MavromatisKendra GrubbLars G SvenssonE Murat TuzcuPeter C BlockVijay IyerVasilis BabaliarosSamir R KapadiaHabib SamadyPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Among patients who underwent both PCI and TAVR, history of CABG, higher BMI, and statin therapy had lower, while those discharged on warfarin, had higher adverse event rates. Adverse events rates were similar regardless of timing of PCI.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- atrial fibrillation
- acute myocardial infarction
- coronary artery bypass grafting
- acute coronary syndrome
- patients undergoing
- antiplatelet therapy
- aortic stenosis
- st segment elevation myocardial infarction
- transcatheter aortic valve replacement
- st elevation myocardial infarction
- aortic valve
- body mass index
- cardiovascular disease
- coronary artery bypass
- venous thromboembolism
- stem cells
- direct oral anticoagulants
- emergency department
- heart failure
- clinical trial
- left ventricular
- type diabetes
- randomized controlled trial
- replacement therapy
- open label